Viridian Therapeutics (VRDN) Q3 2025 results reflect significant recent licensing revenue offsetting substantial R&D expansion, followed by major post-period financing activities that significantly bolstered liquidity.
Financial Performance (9 Months Ended 9/30/2025): Total revenue reached \(70.7M, driven primarily by a \)70.0M upfront license payment from the Kissei Agreement (Japan rights for veligrotug/VRDN-003). Despite this revenue, the Net Loss widened to \(\\)(222.2)M\( (up from \)$(190.2)M\( in 2024) due to sharply increased R&D spending (\)233.5M YTD). Quarterly performance (Q3) improve
...